<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04567147</url>
  </required_header>
  <id_info>
    <org_study_id>CAUDepression-01</org_study_id>
    <nct_id>NCT04567147</nct_id>
  </id_info>
  <brief_title>Effect of Probiotic on Depression</brief_title>
  <official_title>Effect of Probiotic on Depressive Symptom in Chinese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Agricultural University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Agricultural University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depressive disorder, also known as depression, is a type of mood disorder characterized by&#xD;
      persistent low mood. The incidence of depression worldwide is about 6%. Growing evidence&#xD;
      suggested that the gut microbiota plays a key role in the development of depression.&#xD;
      Probiotics can effectively regulate gut microbiota, and showed potential in alleviating&#xD;
      depression. This study investigated the effect of formula probiotic (containing Lactobacillus&#xD;
      paracasei, Bifidobacterium animalis, Bifidobacterium longum, Bifidobacterium bifidum and&#xD;
      Lactobacillus plantarum) on depression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2018</start_date>
  <completion_date type="Actual">September 12, 2020</completion_date>
  <primary_completion_date type="Actual">June 22, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale</measure>
    <time_frame>Changes in the HAMD score at baseline and 8-week intervention</time_frame>
    <description>Depressive symptoms as measured with the Hamilton Rating Scale for Depression. The score rangs from 0 to 53. The higher score means severer depressive symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fecal microbiome</measure>
    <time_frame>Changes between at baseline and 8-week intervention</time_frame>
    <description>changes in the profile of gut microbiota before and after 8-week intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Il-1β</measure>
    <time_frame>change from baseline to intervention measurements at 8 weeks</time_frame>
    <description>Serum Il-1β levels before and after intervention assessed by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Il-6</measure>
    <time_frame>change from baseline to intervention measurements at 8 weeks</time_frame>
    <description>Serum Il-6 levels before and after intervention assessed by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum TNF-α</measure>
    <time_frame>change from baseline to intervention measurements at 8 weeks</time_frame>
    <description>Serum TNF-α levels before and after intervention assessed by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cortisol</measure>
    <time_frame>change from baseline to intervention measurements at 8 weeks</time_frame>
    <description>Serum cortisol levels before and after intervention assessed by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Brain-derived neurotrophic factor</measure>
    <time_frame>change from baseline to intervention measurements at 8 weeks</time_frame>
    <description>Serum Brain-derived neurotrophic factor levels before and after intervention assessed by ELISA.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formula probiotic contains freeze-dried Lactobacillus casei, Bafidobacterium animals, Bifidobacterium longum, Bifidobacterium bidium and Lactobacillus plantarum, each at a dosage of 3.0E+10 CFU per 2g sachet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo made with only the excipients. The placebo sachet was matched to the study probiotic products for taste, color, and size.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Patients received the formula probiotic for consecutive 8 weeks ( one sachet per day ).</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients received the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal body mass index ≥ 18.5 until ≤ 29.9&#xD;
&#xD;
          -  Mild to moderate major depression diagnosed by psychiatrists according to the&#xD;
             diagnostic criteria for depressive episodes in DSM-5 (American Diagnostic and&#xD;
             Statistical Manual of Mental Disorders (Fifth Edition))&#xD;
&#xD;
          -  Hamilton Rating Scale for Depression (HAMD-17) score not less than 8&#xD;
&#xD;
          -  Agreed to intake study product during the study period&#xD;
&#xD;
          -  Agreed to sign written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of systemic antibiotics or antimycotics medication in the 30 days prior to the&#xD;
             study&#xD;
&#xD;
          -  Investigator's uncertainty about the willingness or ability of subject to comply with&#xD;
             the protocol requirements&#xD;
&#xD;
          -  Persons with a milk protein allergy, lactose intolerance&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Subject had other serious diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Chinese Medicine Hospital Pinggu Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyttenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine JP, Levinson D, Matschinger H, Mora ME, Browne MO, Posada-Villa J, Viana MC, Williams DR, Kessler RC. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011 Jul 26;9:90. doi: 10.1186/1741-7015-9-90.</citation>
    <PMID>21791035</PMID>
  </reference>
  <results_reference>
    <citation>Aizawa E, Tsuji H, Asahara T, Takahashi T, Teraishi T, Yoshida S, Ota M, Koga N, Hattori K, Kunugi H. Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder. J Affect Disord. 2016 Sep 15;202:254-7. doi: 10.1016/j.jad.2016.05.038. Epub 2016 May 24.</citation>
    <PMID>27288567</PMID>
  </results_reference>
  <results_reference>
    <citation>Wallace CJK, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry. 2017 Feb 20;16:14. doi: 10.1186/s12991-017-0138-2. eCollection 2017. Review. Erratum in: Ann Gen Psychiatry. 2017 Mar 7;16:18.</citation>
    <PMID>28239408</PMID>
  </results_reference>
  <results_reference>
    <citation>Kazemi A, Noorbala AA, Azam K, Eskandari MH, Djafarian K. Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial. Clin Nutr. 2019 Apr;38(2):522-528. doi: 10.1016/j.clnu.2018.04.010. Epub 2018 Apr 24.</citation>
    <PMID>29731182</PMID>
  </results_reference>
  <results_reference>
    <citation>Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, Jafari P, Akbari H, Taghizadeh M, Memarzadeh MR, Asemi Z, Esmaillzadeh A. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. Nutrition. 2016 Mar;32(3):315-20. doi: 10.1016/j.nut.2015.09.003. Epub 2015 Sep 28.</citation>
    <PMID>26706022</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 20, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>September 25, 2020</last_update_submitted>
  <last_update_submitted_qc>September 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Agricultural University</investigator_affiliation>
    <investigator_full_name>Fazheng Ren</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

